InvestorsHub Logo
Followers 28
Posts 4304
Boards Moderated 1
Alias Born 09/22/2006

Re: None

Thursday, 07/11/2019 8:50:59 AM

Thursday, July 11, 2019 8:50:59 AM

Post# of 8489
Halozyme analyst at Cantor Fitzgerald Halozyme price target raised to $27 from $24 at Cantor Fitzgerald. Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.

Read more at:
https://thefly.com/landingPageNews.php?id=2928258

The more you know, the less you don't know.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News